SGLT2 inhibitors in type 2 diabetes: time to flozinate?

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a wide range of benefits in people with insufficiently controlled type 2 diabetes. Claire Davies provides an overview of these drugs to support safe use in primary care Sodium-glucose cotransporter-2 (SGLT2) inhibitors, sometimes also referred to as ‘gliflozins’ or ‘flozins’, are an established class of medications used for the treatment of insufficiently controlled type 2 diabetes. This article provides a summary of everything nursing staff in primary care need to know about the use of SGLT2 inhibitors for type 2 diabetes to support safe prescribing, monitoring and use.